Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.70
ABBV's Cash to Debt is ranked higher than
55% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 68.42 vs. ABBV: 0.70 )
ABBV' s 10-Year Cash to Debt Range
Min: 0.5   Max: No Debt
Current: 0.7

Equity to Asset 0.18
ABBV's Equity to Asset is ranked higher than
51% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. ABBV: 0.18 )
ABBV' s 10-Year Equity to Asset Range
Min: 0.11   Max: 0.69
Current: 0.18

0.11
0.69
Interest Coverage 18.94
ABBV's Interest Coverage is ranked higher than
55% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ABBV: 18.94 )
ABBV' s 10-Year Interest Coverage Range
Min: 18.94   Max: 9999.99
Current: 18.94

18.94
9999.99
F-Score: 7
Z-Score: 4.04
M-Score: -2.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 30.14
ABBV's Operating margin (%) is ranked higher than
95% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -68.50 vs. ABBV: 30.14 )
ABBV' s 10-Year Operating margin (%) Range
Min: 20.76   Max: 34.7
Current: 30.14

20.76
34.7
Net-margin (%) 21.97
ABBV's Net-margin (%) is ranked higher than
94% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. ABBV: 21.97 )
ABBV' s 10-Year Net-margin (%) Range
Min: 19.68   Max: 32.62
Current: 21.97

19.68
32.62
ROE (%) 91.90
ABBV's ROE (%) is ranked higher than
99% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. ABBV: 91.90 )
ABBV' s 10-Year ROE (%) Range
Min: 28.09   Max: 156.85
Current: 91.9

28.09
156.85
ROA (%) 14.14
ABBV's ROA (%) is ranked higher than
96% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -17.51 vs. ABBV: 14.14 )
ABBV' s 10-Year ROA (%) Range
Min: 14.14   Max: 19.53
Current: 14.14

14.14
19.53
ROC (Joel Greenblatt) (%) 148.94
ABBV's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 876 Companies
in the Global Biotechnology industry.

( Industry Median: -201.33 vs. ABBV: 148.94 )
ABBV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 122.82   Max: 149.5
Current: 148.94

122.82
149.5
» ABBV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ABBV Guru Trades in Q3 2013

Jeremy Grantham 519,190 sh (+2337.51%)
Jim Simons 1,991,500 sh (+268.59%)
Joel Greenblatt 141,954 sh (+39.51%)
Paul Tudor Jones 353,100 sh (+0.89%)
Manning & Napier Advisors, Inc 227,657 sh (+0.65%)
Murray Stahl 33,840 sh (+0.45%)
Vanguard Health Care Fund 8,459,700 sh (unchged)
Mario Gabelli 10,080 sh (unchged)
Jeff Auxier 80,440 sh (unchged)
Robert Bruce 234,300 sh (unchged)
George Soros 165,000 sh (unchged)
John Hussman 403,250 sh (unchged)
Westport Asset Management 180,000 sh (unchged)
Dodge & Cox 37,165 sh (-0.27%)
Tom Russo 86,777 sh (-0.4%)
George Soros 1,000,000 sh (-0.87%)
Pioneer Investments 2,039,509 sh (-1.11%)
PRIMECAP Management 5,892,547 sh (-1.45%)
Bill Frels 268,187 sh (-4.04%)
Ken Fisher 1,065,932 sh (-7.08%)
Steven Cohen 178,199 sh (-65.19%)
» More
Q4 2013

ABBV Guru Trades in Q4 2013

David Dreman 4,572 sh (New)
Steven Cohen 1,088,256 sh (+510.7%)
George Soros 1,147,609 sh (+14.76%)
Ken Fisher 1,140,946 sh (+7.04%)
Bill Frels 279,694 sh (+4.29%)
Murray Stahl 35,285 sh (+4.27%)
Westport Asset Management 180,000 sh (unchged)
Tom Russo 86,777 sh (unchged)
Mario Gabelli 10,080 sh (unchged)
Pioneer Investments 2,037,103 sh (-0.12%)
PRIMECAP Management 5,850,670 sh (-0.71%)
Robert Bruce 231,300 sh (-1.28%)
Dodge & Cox 36,649 sh (-1.39%)
Jeff Auxier 78,440 sh (-2.49%)
Jim Simons 1,809,600 sh (-9.13%)
John Hussman 303,250 sh (-24.8%)
Joel Greenblatt 103,981 sh (-26.75%)
Manning & Napier Advisors, Inc 149,065 sh (-34.52%)
Jeremy Grantham 284,091 sh (-45.28%)
Paul Tudor Jones 76,100 sh (-78.45%)
Vanguard Health Care Fund 1,739,600 sh (-79.44%)
» More
Q1 2014

ABBV Guru Trades in Q1 2014

Joel Greenblatt 229,149 sh (+120.38%)
Jim Simons 2,796,900 sh (+54.56%)
PRIMECAP Management 6,335,722 sh (+8.29%)
Mario Gabelli 10,462 sh (+3.79%)
Murray Stahl 35,882 sh (+1.69%)
Pioneer Investments 2,045,676 sh (+0.42%)
Dodge & Cox 36,701 sh (+0.14%)
Robert Bruce 231,300 sh (unchged)
John Hussman 303,250 sh (unchged)
Jeff Auxier 78,440 sh (unchged)
Tom Russo 86,777 sh (unchged)
Westport Asset Management 180,000 sh (unchged)
David Dreman Sold Out
Paul Tudor Jones Sold Out
Vanguard Health Care Fund Sold Out
Manning & Napier Advisors, Inc 146,077 sh (-2%)
Bill Frels 269,936 sh (-3.49%)
Ken Fisher 627,139 sh (-45.03%)
Steven Cohen 519,107 sh (-52.3%)
George Soros 350,000 sh (-69.5%)
Jeremy Grantham 66,200 sh (-76.7%)
» More
Q2 2014

ABBV Guru Trades in Q2 2014

Lee Ainslie 3,235,133 sh (New)
NWQ Managers 83,878 sh (New)
Louis Moore Bacon 185,000 sh (New)
Paul Tudor Jones 257,344 sh (New)
Ken Fisher 1,104,609 sh (+76.13%)
Manning & Napier Advisors, Inc 192,029 sh (+31.46%)
Robert Bruce 231,300 sh (unchged)
Westport Asset Management 180,000 sh (unchged)
Tom Russo 86,777 sh (unchged)
Jeremy Grantham Sold Out
Dodge & Cox 36,649 sh (-0.14%)
PRIMECAP Management 6,304,122 sh (-0.5%)
Mario Gabelli 10,382 sh (-0.76%)
John Hussman 300,000 sh (-1.07%)
Pioneer Investments 2,014,581 sh (-1.52%)
Murray Stahl 35,273 sh (-1.7%)
Bill Frels 264,316 sh (-2.08%)
Jeff Auxier 73,421 sh (-6.4%)
Jim Simons 2,233,600 sh (-20.14%)
George Soros 150,000 sh (-57.14%)
Joel Greenblatt 88,923 sh (-61.19%)
» More
» Details

Insider Trades

Latest Guru Trades with ABBV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Lee Ainslie 2014-06-30 New Buy2.6%$46.46 - $56.79 $ 55.25%3235133
Joel Greenblatt 2014-06-30 Reduce -61.19%0.11%$46.46 - $56.79 $ 55.25%88923
George Soros 2014-06-30 Reduce -57.14%0.1%$46.46 - $56.79 $ 55.25%150000
George Soros 2014-03-31 Reduce -69.5%0.35%$46.83 - $53.68 $ 55.29%350000
Vanguard Health Care Fund 2014-03-31 Sold Out 0.28%$46.83 - $53.68 $ 55.29%0
Joel Greenblatt 2014-03-31 Add 120.38%0.1%$46.83 - $53.68 $ 55.29%229149
David Dreman 2014-03-31 Sold Out 0.02%$46.83 - $53.68 $ 55.29%0
Vanguard Health Care Fund 2013-12-31 Reduce -79.44%1.03%$44.52 - $54.32 $ 55.212%1739600
John Hussman 2013-12-31 Reduce -24.8%0.25%$44.52 - $54.32 $ 55.212%303250
Joel Greenblatt 2013-12-31 Reduce -26.75%0.06%$44.52 - $54.32 $ 55.212%103981
David Dreman 2013-12-31 New Buy0.02%$44.52 - $54.32 $ 55.212%4572
Joel Greenblatt 2013-09-30 Add 39.51%0.06%$42.21 - $47.92 $ 55.224%141954
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on AbbVie Inc

Lountzis Asset Management Comments on Abbvie - Mar 21, 2014

ABBVIE (ABBV), spun off from Abbott, represents their research-based proprietary pharmaceutical business and is led by its highly profitable Humira franchise. Humira makes up approximately 50% of revenues and over 70% of profits. While AbbVie is focused on growing its pipeline, the reality is Humira, the leading rheumatoid arthritis drug, will continue to drive the revenue and profit growth for AbbVie until some of the experimental drugs they are working on such as its Hepatitis C virus drug gains FDA approval and enters the market. As a result, we are reviewing our holding of AbbVie at this time given its enormous concentration on one drug. While it continues to lead in many areas and it continues to grow around the world, it remains a concern for us. AbbVie’s revenues in 2013 exceeded $18.8 billion with operating earnings of $5.7 billion.



From Lountzis Asset Management 2013 Annual Letter



Check out latest stock trades

Top Ranked Articles about AbbVie Inc

The 5 Most-Owned Spin-Offs of Investment Gurus
Numerous financiers, including Joel Greenblatt (Trades, Portfolio), have posited that investors can beat the market by investing in spin-offs – small portions of larger companies separated to stand as their own, independent company. But is this true? This is a question that GuruFocus writer Vera Yuan pondered in her article, “Can Spin-Offs Beat the Market?” Her research concluded that 52 weeks after being spun off, all spun-off companies since 2009 collectively outperformed the market by 84.28%. For this reason, GuruFocus introduced the “Spin-Off List” screener, which tracks all companies spun off since 2013. Read more...
Lountzis Asset Management Comments on Abbvie
ABBVIE (ABBV), spun off from Abbott, represents their research-based proprietary pharmaceutical business and is led by its highly profitable Humira franchise. Humira makes up approximately 50% of revenues and over 70% of profits. While AbbVie is focused on growing its pipeline, the reality is Humira, the leading rheumatoid arthritis drug, will continue to drive the revenue and profit growth for AbbVie until some of the experimental drugs they are working on such as its Hepatitis C virus drug gains FDA approval and enters the market. As a result, we are reviewing our holding of AbbVie at this time given its enormous concentration on one drug. While it continues to lead in many areas and it continues to grow around the world, it remains a concern for us. AbbVie’s revenues in 2013 exceeded $18.8 billion with operating earnings of $5.7 billion. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 21.40
ABBV's P/E(ttm) is ranked higher than
95% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ABBV: 21.40 )
ABBV' s 10-Year P/E(ttm) Range
Min: 9.86   Max: 22.47
Current: 21.4

9.86
22.47
P/B 16.70
ABBV's P/B is ranked lower than
58% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ABBV: 16.70 )
ABBV' s 10-Year P/B Range
Min: 15.49   Max: 25.22
Current: 16.7

15.49
25.22
P/S 4.60
ABBV's P/S is ranked higher than
80% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 17.18 vs. ABBV: 4.60 )
ABBV' s 10-Year P/S Range
Min: 2.83   Max: 4.86
Current: 4.6

2.83
4.86
PFCF 18.20
ABBV's PFCF is ranked higher than
95% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ABBV: 18.20 )
ABBV' s 10-Year PFCF Range
Min: 8.64   Max: 19.41
Current: 18.2

8.64
19.41
EV-to-EBIT 16.21
ABBV's EV-to-EBIT is ranked higher than
95% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ABBV: 16.21 )
ABBV' s 10-Year EV-to-EBIT Range
Min: 10.3   Max: 17
Current: 16.21

10.3
17
Current Ratio 2.82
ABBV's Current Ratio is ranked higher than
65% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. ABBV: 2.82 )
ABBV' s 10-Year Current Ratio Range
Min: 1.22   Max: 2.82
Current: 2.82

1.22
2.82
Quick Ratio 2.65
ABBV's Quick Ratio is ranked higher than
67% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ABBV: 2.65 )
ABBV' s 10-Year Quick Ratio Range
Min: 1.06   Max: 2.65
Current: 2.65

1.06
2.65

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.00
ABBV's Dividend Yield is ranked higher than
91% of the 168 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. ABBV: 3.00 )
ABBV' s 10-Year Dividend Yield Range
Min: 0.85   Max: 3.44
Current: 3

0.85
3.44
Dividend Payout 0.62
ABBV's Dividend Payout is ranked higher than
92% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ABBV: 0.62 )
ABBV' s 10-Year Dividend Payout Range
Min: 0.57   Max: 0.67
Current: 0.62

0.57
0.67
Yield on cost (5-Year) 3.00
ABBV's Yield on cost (5-Year) is ranked higher than
86% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 1.20 vs. ABBV: 3.00 )
ABBV' s 10-Year Yield on cost (5-Year) Range
Min: 0.85   Max: 3.44
Current: 3

0.85
3.44

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.10
ABBV's Price/Median PS Value is ranked higher than
69% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. ABBV: 1.10 )
ABBV' s 10-Year Price/Median PS Value Range
Min: 0.73   Max: 1.17
Current: 1.1

0.73
1.17
Earnings Yield (Greenblatt) 6.20
ABBV's Earnings Yield (Greenblatt) is ranked higher than
67% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ABBV: 6.20 )
ABBV' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.9   Max: 9.7
Current: 6.2

5.9
9.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:ABBV.Switzerland, ABBV.France, 4AB.Germany, 0QCV.country
AbbVie Inc was incorporated in Delaware on April 10, 2012, and is a wholly owned subsidiary of Abbott. The company is a research-based biopharmaceutical company with portfolio of proprietary products including a broad line of adult and pediatric pharmaceuticals. The company discovers, develops, manufactures and sells proprietary pharmaceutical products. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis complications. AbbVie also has a pipeline of new medicines, including more than 20 compounds or indications in Phase II or Phase III development across such important medical specialties as immunology, renal care, hepatitis C, women's health, oncology, and neuroscience, including multiple sclerosis and Alzheimer's disease. AbbVie operates in one business segment—pharmaceutical products. AbbVie competes with other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market, and sell proprietary pharmaceutical products and biologics.
» More Articles for ABBV

Headlines

Articles On GuruFocus.com
Jeff Auxier Second Quarter Shareholder Letter Aug 08 2014 
AbbVie´s ROE: A Tremendous Ratio Jul 27 2014 
Why AbbVie Looks Like a Sell Jul 18 2014 
Why Gilead Sciences Will Grow to $100 Jul 18 2014 
Why I Bought Baxter International Jun 19 2014 
The Top 5 Guru-Held Spin-Offs Jun 06 2014 
Competition From AbbVie Will Not Hurt Gilead Sciences Apr 27 2014 
Abbvie Inc. (ABBV) Dividend Stock Analysis Mar 21 2014 
Lountzis Asset Management Comments on Abbvie Mar 21 2014 
Companies That Increased Dividends Lately Feb 24 2014 


More From Other Websites
What You Need To Know About New Restrictions On Hydrocodone Combinations Aug 22 2014
Form 8.3 - ABBVIE INC Aug 22 2014
[video] David Marcus Discusses the Policy Aspects of Corporate Inversions Aug 21 2014
ABBVIE INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Aug 21 2014
[video] Cramer's Stop Trading: Gilead Sciences Aug 21 2014
Rule 2.10 Announcement Aug 21 2014
Form 8.3 - ABBVIE INC Aug 20 2014
Rule 2.10 Announcement Aug 20 2014
Rule 2.10 Announcement Aug 19 2014
Term Loan Credit Agreement Aug 19 2014
AbbVie Cystic Fibrosis Scholarship Program Awards 40 Student Scholars With Annual Academic Awards Aug 18 2014
[video] Latest motif: Tax inversion targets Aug 18 2014
AbbVie Cystic Fibrosis Scholarship Program Awards 40 Student Scholars With Annual Academic Awards Aug 18 2014
Rule 2.10 Announcement Aug 18 2014
UK Says Sovaldi Is Worth It. We Should Listen. Aug 17 2014
Abbott, AbbVie Win Dismissal of Suit Over Depakote Marketing Aug 15 2014
Biotech Leader Gilead Sciences Scores Sovaldi Win Aug 15 2014
Gilead Wins Sovaldi Dispute With Roche, U.K. Nod Aug 15 2014
INVESTOR ALERT: Investigation of AbbVie Inc. Announced by The Wagner Firm Aug 15 2014
Form 8.3 - ABBVIE INC Aug 15 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide